Keflavo (Micronised Purified Flavonoic Fraction)

The fraction consists of flavonoid molecules that act as free‑radical scavengers and modulate enzymes such as cyclooxygenase and lipoxygenase. By influencing oxidative stress pathways, it may affect vascular tone and inflammatory signaling, although the exact clinical mechanisms remain under investigation.

The dosage of Keflavo is determined by the prescribing healthcare professional based on the specific research protocol or clinical context. No standardized dosing regimen is publicly established, and the prescriber should define the appropriate amount.

Safety data for Micronised Purified Flavonoic Fraction in pregnancy and lactation are insufficient. It is generally recommended to avoid use during pregnancy and breastfeeding unless the potential benefit clearly outweighs the unknown risk, and only under medical supervision.

To request Keflavo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Keflavo provides a micronised, purified flavonoic fraction, offering higher bioavailability than many crude flavonoid extracts. Compared with generic flavonoid powders, its standardized composition and micronisation may result in more consistent pharmacological activity, though direct clinical comparisons are limited.

Keflavo should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct sunlight. Ensure the container is tightly closed to maintain product stability throughout its shelf life.

Keflavo is intended for oral administration. The exact form (e.g., tablet, capsule, powder) is determined by the supplier, and it should be taken according to the prescribing professional’s instructions, typically with water and possibly with food to reduce gastrointestinal irritation.

Serious risks, although rare, include hypersensitivity reactions such as rash, pruritus, or anaphylaxis. In patients taking anticoagulants, there is a potential for increased bleeding. Monitoring for these events is advisable, especially during prolonged use or in vulnerable populations.

Individuals with known hypersensitivity to flavonoid compounds should avoid Keflavo. It is also not recommended for pregnant or breastfeeding women unless a healthcare provider determines that the potential benefit justifies the possible risk.